Grifols (GRF): analysis in plain words

Is Grifols cheap or expensive? How it makes money, whether it grows and its risks, explained in plain words and with its official accounts.

Fintols explains Grifols (GRF) in plain words for people starting to invest: how it makes money, whether it is growing, what protects it, whether it looks cheap or expensive and what could go wrong. Using the numbers from its official accounts and without telling you what to buy.

Grifols (GRF) trades on the Madrid Stock Exchange and operates in healthcare. Makes medicines derived from blood plasma and diagnostic equipment.

What to look at in Grifols if you are starting out

Before looking at the Grifols share price, it helps to understand six things. The Fintols analysis answers them in this order, with the numbers from its accounts and every difficult word explained.

1. How Grifols makes money

A company in healthcare like Grifols usually sells medicines, medical devices or health services to hospitals, governments and patients. The report shows which part of its sales comes from each business and each region of the world.

2. Whether it is really growing

What matters is whether it has new products to replace the ones losing protection. Fintols compares its sales and profit with a year ago and tells you in one sentence whether things are getting better or worse.

3. What protects it from competitors

In healthcare, the defence is usually patents, the years of trials a rival needs and the trust of doctors. A well-protected company can keep what it earns for years.

4. Whether it is cheap or expensive

Fintols estimates what GRF could be worth if things go badly, normally or very well, and compares it with what it costs today. It is not a prediction: it is a way to see whether the price already assumes a very good future.

5. What it does with its profit

It can reinvest to grow, buy back its own shares or pay it out as a dividend. That mix says a lot about its priorities.

6. What could go wrong

The typical risks in healthcare are patents expiring, a drug in development failing and prices set by governments. The report explains each one and what would happen if it occurred.

Next step

Open the full GRF analysis with its valuation and scenarios.

Related analyses

Frequently asked questions about GRF

Should I buy Grifols stock?

Fintols does not give buy or sell recommendations. The report shows the data and scenarios so you can decide with judgement or ask a licensed adviser.

Where does the GRF data come from?

From the official EU annual report (ESEF format) and market data, checked before the analysis is written. If a figure does not exist, we show N/A.

Is the GRF analysis free?

Yes. The free plan includes 1 stock analysis a day, no card. See also the PRO plans.